Detection of early adenocarcinoma of the esophagogastric junction by spraying an enzyme-activatable fluorescent probe targeting Dipeptidyl peptidase-IV
Authors:
- Keiko YamamotoKYKeiko Yamamoto
- Shunsuke OhnishiSOShunsuke Ohnishi
- Takeshi MizushimaTMTakeshi Mizushima
- Junichi KodairaJKJunichi Kodaira
- Masayoshi OnoMOMasayoshi Ono
- Yutaka HatanakaYHYutaka Hatanaka
- Kanako C. HatanakaKHKanako C. Hatanaka
- Yugo KurikiYKYugo Kuriki
- Mako KamiyaMKMako Kamiya
- Nobuyuki EhiraNENobuyuki Ehira
- Keisuke ShinadaKSKeisuke Shinada
- Hiroaki TakahashiHTHiroaki Takahashi
Open Access
- 28 January 2020
- journal article
- research article
- Published by Springer Nature in BMC Cancer
- Vol. 20 (1) , 1-9
Abstract
Background: It is still difficult to detect and diagnose early adenocarcinoma of the esophagogastric junction (EGJ) using conventional endoscopy or image-enhanced endoscopy. A glutamylprolyl hydroxymethyl rhodamine green (EP-HMRG) fluorescent probe that can be enzymatically activated to become fluorescent after the cleavage of a dipeptidyl peptidase (DPP)-IV-specific sequence has been developed and is reported to be useful for the detection of squamous cell carcinoma of the head and neck, and esophagus; however, there is a lack of studies that focuses on detecting EGJ adenocarcinoma by fluorescence molecular imaging. Therefore, we investigated the visualization of early EGJ adenocarcinoma by applying EP-HMRG and using clinical samples resected by endoscopic submucosal dissection (ESD).Methods: Fluorescence imaging with EP-HMRG was performed in 21 clinical samples resected by ESD, and the fluorescence intensity of the tumor and non-tumor regions of interest was prospectively measured. Immunohistochemistry was also performed to determine the expression of DPP-IV.Results: Fluorescence imaging of the clinical samples showed that the tumor lesions were visualized within a few minutes after the application of EP-HMRG, with a sensitivity, specificity, and accuracy of 85.7, 85.7, and 85.7%, respectively. However, tumors with a background of intestinal metaplasia did not have a sufficient contrast-to-background ratio since complete intestinal metaplasia also expresses DPP-IV. Immunohistochemistry measurements revealed that all fluorescent tumor lesions expressed DPP-IV.Conclusions: Fluorescence imaging with EP-HMRG could be useful for the detection of early EGJ adenocarcinoma lesions that do not have a background of intestinal metaplasia.Keywords
All Related Versions
Funding Information
- Grant-in-Ai (JSPS, 17K09343)
This publication has 31 references indexed in Scilit:
- American Gastroenterological Association Technical Review on the Management of Barrett's EsophagusGastroenterology, 2011
- American Gastroenterological Association Medical Position Statement on the Management of Barrett's EsophagusGastroenterology, 2011
- Adenocarcinoma of the esophagogastric junction: incidence, characteristics, and treatment strategiesGastric Cancer, 2010
- Epidemiology of esophageal cancer: Orient to Occident. Effects of chronology, geography and ethnicityJournal of Gastroenterology and Hepatology, 2009
- Lower esophageal palisade vessels and the definition of Barrett's esophagusDiseases of the Esophagus, 2008
- Seprase, Dipeptidyl Peptidase IV and Urokinase-Type Plasminogen Activator Expression in Dysplasia and Invasive Squamous Cell Carcinoma of the EsophagusOncology, 2008
- Distribution and significance of the oesophageal and gastric cardiac mucosae: a study of 131 operation specimensHistopathology, 2007
- Are screening and surveillance for Barrett’s oesophagus really worthwhile?: Table 1Gut, 2005
- CD26 (dipeptidyl peptidase IV/DPP IV) as a novel molecular marker for differentiated thyroid carcinomaInternational Journal of Cancer, 1995
- Barrett's EsophagusNew England Journal of Medicine, 1986